Uveitis

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Retrieved on: 
Tuesday, April 26, 2022
Patent, CEO, European Patent Convention, Biotechnology, Multiple sclerosis, Lymphatic system, Retinopathy, NASDAQ, EPO, Immune tolerance, CFO, Laquinimod, Patient, Corneal neovascularization, ACTI, Multiple myeloma, III, EU, Choroidal neovascularization, Eye, United States patent law, European Patent Office, Partnership, Premature, MS, Uveitis, Therapy, Pharmaceutical industry

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotechs patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization.

Key Points: 
  • Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotechs patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization.
  • The patent will be granted on May 11, 2022, under patent number EP 3886858, and provides protection and market exclusivity of laquinimod in this field of use until 2040.
  • The patent covers the medical use of laquinimod for treatment of sight-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy.
  • The now granted European patent of laquinimod further strengthens the protection of laquinimod in devastating eye disorders with high medical need, said Helen Tuvesson, CEO.

Celltrion Healthcare announces the availability of Yuflyma®, a high-concentration, low-volume, citrate-free, and latex-free Humira® (adalimumab) biosimilar in Canada

Retrieved on: 
Monday, April 11, 2022
CONNECT, CGMP, Crohn's disease, Letter, AbbVie, Uveitis, Patient, Adult, Psoriatic arthritis, Celltrion, Program, Ulcerative colitis, Pan-Canadian Pharmaceutical Alliance, Commercial, Psoriasis, EU, Hidradenitis suppurativa, Rheumatoid arthritis, Gastroenterology, Ankylosing spondylitis, Pharmacy, McMaster University, FDA, Division, Health Canada, Pharmaceutical industry, Medical device, Kerosene, Medicine, Adalimumab

"We received a positive letter of intent from the pan-Canadian Pharmaceutical Alliance, with coverage by provincial formularies soon to come.

Key Points: 
  • "We received a positive letter of intent from the pan-Canadian Pharmaceutical Alliance, with coverage by provincial formularies soon to come.
  • With the launch of Yuflyma, Celltrion Healthcare Canada is also proud to offer CELLTRION CONNECT, a patient-focused support program tailored to support patients and healthcare providers.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • YUFLYMA is a registered trademark of Celltrion Inc.
    REMSIMA SC is a trademark of Celltrion Inc.
    HUMIRA is a registered trademark of AbbVie Inc.

Innovation1 Biotech (IVBT) Completes Name and Ticker Symbol Change from Gridiron BioNutrients (GMVP)

Retrieved on: 
Monday, April 4, 2022
Company, Private Securities Litigation Reform Act, Drug development, Sale, Chronic fatigue syndrome, Marketing, Uveitis, Post-traumatic stress disorder, Growth, Fibromyalgia, Schedule 1, ACT Biotech Inc, CEO, U.S. Securities and Exchange Commission, Mineral, Review, Intellectual property, GLOBE, OTCQB, Income, Cannabis, Depression, Fatigue, Acquisition, Security (finance), Pharmaceutical industry

In conjunction with the name change, the Companys ticker symbol will be changed to IVBT effective at the open of market trading today, April 4, 2022.

Key Points: 
  • In conjunction with the name change, the Companys ticker symbol will be changed to IVBT effective at the open of market trading today, April 4, 2022.
  • The name and ticker symbol change align with Innovation1s goal to become a leader in the development of modified Schedule 1 molecules of botanical origin and to deliver innovative change in the psychedelic and cannabinoid space.
  • Today marks a key milestone in our transformation into a biopharmaceutical pioneer, said Jeffrey Kraws, CEO of Innovation1 Biotech.
  • Words such as anticipate, believe, estimate, expect, intendand similar expressions, as they relate to Innovation1 Biotech Inc. (the Company) or its management, identify forward-looking statements.

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Retrieved on: 
Thursday, March 31, 2022
BLA, Therapy, DME, Retinal, Research, Mab, CATT, PIER, MD, Biologics license application, VEGF, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Annual report, Security (finance), KDR, Pharmacy, Marketing, Risk, UCLA School of Dentistry, Bevacizumab, Retina, Hope, U.S. Securities and Exchange Commission, Terminology, Ranibizumab, AMD, Clinical trial, Public health, Endothelium, BRVO, Inflammation, FDA, Patient, Company, Human, Uveitis, Diosynth, Food, National Eye, Safety, National Eye Institute, File association, COVID-19, Physician, David Geffen School of Medicine at UCLA, Effectiveness, Pharmaceutical industry, Outlook, Ophthalmology, Ophthalmology

If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.

Key Points: 
  • If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • If approved, ONS-5010 can replace the need to use unapproved repackaged IV bevacizumab from compounding pharmacies for the treatment of wet AMD.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

Vitreoretinal Surgery Devices Market to Witness Dynamic Growth at an Increased CAGR of 7.73% Reaching USD 2.45 Billion by 2026, Research Report | DelveInsight

Retrieved on: 
Monday, March 28, 2022
Paragon, Bausch & Lomb, Therapy, CAGR, Diabetic retinopathy, Diabetes, Uveitis, Forecasting, Freeflow, International, Company, Silicone, Gas, USD, Retina, Eye, Vitreous hemorrhage, Growth, Macular degeneration, Government, Awareness, FDA, Retinal detachment, Partnership, Johnson & Johnson Vision, FCI, Eye surgery, LAS, Prevalence, Epiretinal membrane, COVID-19, Dentistry, Pharmaceutical industry, Hospital, Health insurance, BVI

LAS VEGAS, March 28, 2022 /PRNewswire/ -- DelveInsight's Vitreoretinal Surgery Devices Market Insights and Forecast report provides the current and forecast Vitreoretinal Surgery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Vitreoretinal Surgery Devices Market. 

Key Points: 
  • LAS VEGAS, March 28, 2022 /PRNewswire/ --DelveInsight's Vitreoretinal Surgery Devices Market Insights and Forecast report provides the current and forecast Vitreoretinal Surgery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Vitreoretinal Surgery Devices Market.
  • Some of the key takeaways from the Vitreoretinal Surgery Devices Market report:
    As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth in the Vitreoretinal Surgery Devices market.
  • DelveInsight analyzes that the Global Vitreoretinal Surgery Devices Market was valued at USD 1.57 billion in 2020, growing at a CAGR of 7.73% during the forecast period from 2021 to 2026 to reach USD 2.45 billion by 2026.
  • However, on the other hand, postoperative complications of Vitreoretinal Surgery and retinal toxicity of medical devices used during Vitreoretinal Surgery may be certain impeding factors to Vitreoretinal Surgery Devices market growth.

Vial launches Ophthalmology Site Network with Dr. Raj Maturi as the first PI in the network

Retrieved on: 
Thursday, March 24, 2022
National, Baylor University, University School, Indiana University, Diabetic retinopathy, Principal investigator, Uveitis, Baylor College of Medicine, Multimedia, Vial, Macular degeneration, Research, Retina, Clinical Associate (Psychology), CRC, Technology, Acquisition, Lists of countries and territories, Physician, New York University Grossman School of Medicine, SAN, University, Patient, Partnership, Veterinary medicine, Pharmaceutical industry, Ophthalmology

SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- Vial has officially expanded into Ophthalmology with the launch of the Vial Ophthalmology network .

Key Points: 
  • SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- Vial has officially expanded into Ophthalmology with the launch of the Vial Ophthalmology network .
  • Vial strives to be a next generation site management organization by providing the necessary resources for clinics to run trials with faster execution and higher quality.
  • The launch of the Vial Ophthalmology network is marked by the first addition to the site network, Dr. Raj Maturi and his research clinic, Midwest Eye Institute in Indianapolis, IN.
  • Dr. Maturi and his team specialize in retina research, specifically, macular degeneration, diabetic retinopathy, uveitis, and surgical and examination techniques.

VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease

Retrieved on: 
Wednesday, March 23, 2022
Ocular hypertension, ACT Biotech Inc, Sequoia, Trial of the century, Multimedia, Glaucoma, MD, Ophthalmology, Safety, Inflammation, Duane syndrome, GTJA, Day, Patient, Disease, Pharmaceutical industry, Medical imaging, Uveitis

SHANGHAI, March 22, 2022 /PRNewswire/ --VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients with dry eye disease.

Key Points: 
  • SHANGHAI, March 22, 2022 /PRNewswire/ --VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients with dry eye disease.
  • The randomized, double-masked, vehicle-controlled Phase 2 clinical study was conducted at 14 centers across the United States and evaluated the safety and efficacy of VVN001 in patients with dry eye disease.
  • A total of 170 patients were randomized into three groups, VVN001 (5%), VVN001 (1%) or VVN001 vehicle.
  • The results from this phase 2 study will inform the design of future phase 3 clinical studies."

Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Retrieved on: 
Monday, March 21, 2022
LTB4, ARVO, Akari, Private Securities Litigation Reform Act, Therapy, Retina, Drug development, Risk, Lung, EAC, AMD, Uveitis, Food, HIV disease progression rates, European Medicines Agency, Comparison, Complement, Failure, UCL, SEC, TMA, GA, U.S. Securities and Exchange Commission, Diabetic retinopathy, Poster, Leukotriene, Inflammation, UCL Institute of Ophthalmology, BP, Institute, Nasdaq, COVID-19, Leukotriene B4, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellectual property, GLOBE, EMA, Antimicrobial, Moorfields Eye Hospital, Eye, Thrombotic microangiopathy, Annual report, FDA, Geographic atrophy, Dexamethasone, Patient, Security (finance), Pharmaceutical industry, Ophthalmology

We very much look forward to presenting data on our eye programs at ARVO.

Key Points: 
  • We very much look forward to presenting data on our eye programs at ARVO.
  • There is a significant unmet need in back of the eye diseases including dry AMD and uveitis as well as for surface of the eye inflammatory conditions.
  • The poster details are:
    Professor Virginia Calder will present during the Antimicrobial and Immunomodulator Therapeutics session on topical nomacopan in allergic conjunctival disease.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 10, 2022
Bausch & Lomb, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Investor, Suprachoroidal drug delivery, Private Securities Litigation Reform Act, Therapeutic index, Conference call, Pharming, Retina, ET, Diabetic retinopathy, Safety, AMD, Uveitis, Company, Axitinib, GLOBE, Patient, Macular edema, SEC, Review, NASDAQ, Clinical trial, SCS, Choroid, Periodic Report of the United States of America to the United Nations Committee Against Torture, American Academy of Ophthalmology, Annual report, Conference, Acral lentiginous melanoma, U.S. Securities and Exchange Commission, Leadership, Sale, Eye, Income, Cohort, Webcast, Research, Technology, COVID-19, Toxic leukoencephalopathy, Angiogenesis, Food, Pharmaceutical industry, Video game, Animal, Clearside, Ophthalmology

ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
  • Clearsides license and other revenue for the fourth quarter of 2021 was $25.7 million, compared to $11,000 for the fourth quarter of 2020.
  • Research and development expenses for the fourth quarter of 2021 were $3.8 million, compared to $4.5 million for the fourth quarter of 2020.
  • General and administrative expenses for the fourth quarter of 2021 were $3.1 million, compared to $2.6 million for the fourth quarter of 2020.

Global Anterior Uveitis Treatment Market - Growth at a CAGR of 5.8% Expected Between 2021 and 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022
Health, Pharmaceutical, Pupil, Incidence, Prevalence, Uveitis, Light, Disease, Research, Investment, Severe cognitive impairment, COVID-19, Eye, CAGR, Traction, Pharmaceutical industry, Growth

The "Anterior Uveitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anterior Uveitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The anterior uveitis treatment market will show rapid growth due to the increasing cases of the uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.
  • Corticosteroids are found dominating the anterior uveitis treatment market as they are first-line therapies for anterior uveitis and are used in the form of eye drops.
  • They are the most preferred option over biologics however researchers are currently exploring biological therapies for the treatment of anterior uveitis.